Endocrinology, Diabetes & Metabolism (Jul 2020)

The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews

  • Ryan Pelletier,
  • Kelvin Ng,
  • Wajd Alkabbani,
  • Youssef Labib,
  • Nicolas Mourad,
  • John‐Michael Gamble

DOI
https://doi.org/10.1002/edm2.145
Journal volume & issue
Vol. 3, no. 3
pp. n/a – n/a

Abstract

Read online

Abstract Aims To summarize reported cancer events associated with SGLT‐2 inhibitors used in patients with type 2 diabetes mellitus, as well as assess the quality of included reviews. Materials and methods In May 2019, we searched PubMed, Embase and the Cochrane Library for quantitative systematic reviews assessing the safety of SGLT‐2 inhibitors. Data were abstracted using a standardized form, and methodological quality was assessed using the AMSTAR 2 tool. Main outcome measures included total cancer events and specific cancers such as breast cancer, bladder cancer, gastrointestinal cancer, prostate cancer, respiratory cancer, renal cancer and skin cancer. Pooled treatment effects from included reviews were summarized for SGLT‐2 inhibitors as a class and for individual SGLT‐2 inhibitors commonly used worldwide (canagliflozin, dapagliflozin and empagliflozin). Results We screened 1248 unique citations, of which eight quantitative systematic reviews meta‐analysed results from studies reporting the association between an SGLT‐2 inhibitor and any cancer. Only one review was rated as high quality according to AMSTAR 2 assessment. In total, data from 170 cancer‐related point estimates (PE) were reported. As a class, SGLT‐2 inhibitors were not associated with an increased risk of any cancer event versus placebo and active comparators. Most point estimates (7/143) were nonsignificant for individual cancers except for two associations. Empagliflozin was associated with an increased risk of bladder cancer versus placebo and active comparators in two reviews, while canagliflozin appeared protective for gastrointestinal cancer versus placebo and active comparators in one review. Conclusions It appears that SGLT‐2 inhibitors are not associated with an increased risk of total cancer or specific cancers in patients with type 2 diabetes. However, higher quality evidence is needed to derive confident conclusions.

Keywords